

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (Canceled).

Claim 4 (Previously presented) A purified polypeptide comprising a fragment of an amino acid sequence of SEQ ID NO: 2536, wherein said fragment comprises 10 or more consecutive amino acids from said amino acid sequence.

Claims 5-21 (Canceled).

Claim 22 (Previously presented) The purified polypeptide of claim 4, wherein said fragment comprises 12 or more consecutive amino acids from said amino acid sequence.

Claim 23 (Previously presented) The purified polypeptide of claim 4, wherein said fragment comprises 14 or more consecutive amino acids from said amino acid sequence.

Claim 24 (Previously presented) The purified polypeptide of claim 4, wherein said fragment comprises 16 or more consecutive amino acids from said amino acid sequence.

Claim 25 (Previously presented) The purified polypeptide of claim 4, wherein said fragment comprises 18 or more consecutive amino acids from said amino acid sequence.

Claim 26 (Previously presented) The purified polypeptide of claim 4, wherein said fragment comprises 20 or more consecutive amino acids from said amino acid sequence.

Claim 27 (Previously presented) The purified polypeptide of claim 4 further comprising a pharmaceutically acceptable carrier.

Claim 28 (Currently amended) The purified polypeptide of claim 4, wherein the purified polypeptide is immunogenic.

Claims 29-32 (Canceled).